Performance of MRNA Moderna | -16.5% in 12m
Compare MRNA with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?
Compare Moderna with its related Sector/Index XBI
Performance Duell MRNA vs XBI
| TimeFrame | MRNA | XBI |
|---|---|---|
| 1 Day | 1.04% | 3.20% |
| 1 Week | 2.40% | 4.04% |
| 1 Month | 5.55% | -6.95% |
| 3 Months | 12.6% | -1.84% |
| 6 Months | 46.3% | 29.21% |
| 12 Months | -16.5% | 6.43% |
| YTD | -0.92% | -3.21% |
| Rel. Perf. 1m | 1.24 | |
| Rel. Perf. 3m | 2.58 | |
| Rel. Perf. 6m | 1.21 | |
| Rel. Perf. 12m | -2.45 |
Is Moderna a good stock to buy?
No, based on ValueRay Fundamental Analyses, Moderna (NASDAQ:MRNA) is currently (May 2024)
a stock to sell. It has a ValueRay Fundamental Rating of -57.37 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of MRNA as of May 2024 is 105.90. This means that MRNA is currently overvalued and has a potential downside of -4.99% (Sold with Premium).
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of MRNA as of May 2024 is 105.90. This means that MRNA is currently overvalued and has a potential downside of -4.99% (Sold with Premium).
Is MRNA a buy, sell or hold?
- Strong Buy: 10
- Buy: 4
- Hold: 9
- Sell: 1
- Strong Sell: 2
Values above 0%: MRNA is performing better - Values below 0%: MRNA is underperforming
Compare MRNA with Broad Market Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | 3.40% | 9.73% | 27.04% | -38.61% |
| US NASDAQ 100 | QQQ | 3.57% | 10.82% | 27.73% | -48.15% |
| US Dow Jones Industrial 30 | DIA | 3.84% | 9.66% | 31.31% | -29.93% |
| German DAX 40 | DBXD | 3.28% | 7.55% | 26.26% | -29.91% |
| UK FTSE 100 | ISFU | 0.91% | 3.66% | 30.54% | -25.13% |
| Shanghai Shenzhen CSI 300 | CSI 300 | -0.43% | 4.98% | 44.86% | -3.79% |
| Hongkong Hang Seng | HSI | -1.66% | 2.48% | 47.82% | 2.80% |
| Japan Nikkei 225 | EXX7 | 3.16% | 11.57% | 31.50% | -35.41% |
| India NIFTY 50 | INDA | 1.63% | 3.76% | 25.51% | -44.15% |
| Brasil Bovespa | EWZ | 1.88% | 7.69% | 41.07% | -34.32% |
MRNA Moderna vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | 5.20% | 10.06% | 25.99% | -48.88% |
| Consumer Discretionary | XLY | 2.21% | 9.93% | 32.48% | -36.58% |
| Consumer Staples | XLP | 3.60% | 6.51% | 33.94% | -16.08% |
| Energy | XLE | 6.72% | 8.79% | 36.06% | -29.57% |
| Financial | XLF | 4.25% | 9.20% | 21.27% | -40.63% |
| Health Care | XLV | 2.60% | 9.57% | 32.71% | -22.91% |
| Industrial | XLI | 3.11% | 8.57% | 22.37% | -39.04% |
| Materials | XLB | 1.55% | 9.41% | 27.96% | -29.38% |
| Real Estate | XLRE | 3.57% | 12.32% | 35.53% | -16.72% |
| Technology | XLK | 4.30% | 12.54% | 29.62% | -46.21% |
| Utilities | XLU | 1.25% | 2.09% | 32.46% | -17.51% |
| Aerospace & Defense | XAR | 0.74% | 7.15% | 27.98% | -36.37% |
| Biotech | XBI | -1.64% | 12.50% | 17.06% | -22.88% |
| Homebuilder | XHB | 2.83% | 12.77% | 7.34% | -62.40% |
| Retail | XRT | 4.11% | 14.70% | 23.68% | -34.84% |
Does Moderna outperform its market, is MRNA a Sector Leader?
No, over the last 12 months Moderna (MRNA) made -16.45%, while its related Sector, the SPDR S&P Biotech (XBI) made 6.43%.
Over the last 3 months MRNA made 12.56%, while XBI made -1.84%.
No, over the last 12 months Moderna (MRNA) made -16.45%, while its related Sector, the SPDR S&P Biotech (XBI) made 6.43%.
Over the last 3 months MRNA made 12.56%, while XBI made -1.84%.
| Period | MRNA | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 5.55% | -6.95% | -4.18% |
| 3 Months | 12.56% | -1.84% | 2.60% |
| 12 Months | -16.45% | 6.43% | 22.16% |